Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an ...

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a ...

SHOPPING: Give yourself the gift of improved sense of self with the once-a-day treatment that contains ingredients to support ...

Appeasement. Could there be a more ignoble policy? Just ask Chamberlain. Better still, Churchill himself observed that “an ...

Rogaine was approved by the Food and Drug Administration in 1988, the first drug to win the agency’s endorsement for male ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 8% in the afternoon session after the U.S. Food and Drug ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

Within six months, former US Army sergeant Mark Millich began experiencing dizziness, fatigue, cold sweats and was slurring his words - which he described it as feeling 'lobotomized'.

Walgreens was too big to fail entirely–but made too many mistakes and remained in too many dying segments. The Gimlet Eye credits Walgreens for making a good deal with private equity firm Sycamore ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a strong buy.